Palm Beach Gardens, FL, January 8, 2024 – Forward Therapeutics, Inc., a biopharmaceutical company developing next-generation small molecule therapies for chronic immunological and inflammatory disorders, is pleased to announce the appointment of Ajay Madan, Ph.D., as its Chief Development Officer.
“We are excited to welcome Ajay to Forward Therapeutics as we advance our first program into the clinic” said Toufike Kanouni, co-founder and CEO of Forward Therapeutics.
Dr. Madan brings nearly three decades of drug development experience to Forward Therapeutics. He has served in leadership roles at Crinetics Pharmaceuticals and Neurocrine Biosciences. Dr. Madan was the Chief Development Officer at Crinetics, where he served an instrumental role in transitioning the company from drug discovery to a Phase 3 drug development organization. At Neurocrine Biosciences, Dr. Madan led the Ingrezza™ program from its inception in drug discovery to NDA approval. He brings scientific expertise in nonclinical discovery and development, CMC, clinical pharmacology, and regulatory affairs, that will position Forward Therapeutics’ pipeline for success.
“I’m excited to join an outstanding team of drug hunters with a proven track record in discovery and development of novel small molecules,” said. Dr. Madan. “I look forward to contributing to advancing Forward’s lead asset into the clinic, while building its pipeline for the treatment of a variety of immunological and inflammatory diseases.”
About Forward Therapeutics
Forward Therapeutics is a biopharmaceutical company dedicated to transforming the treatment of chronic inflammatory disorders. The company is advancing a pipeline of novel, next-generation small molecule immune therapies. To learn more, please visit www.forward-tx.com and follow us on LinkedIn.